News and Announcements
Innate Immuno’s MS Trial Drug Gets Global Spotlight
- Published October 12, 2012 9:38PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Auckland, NZ, October 12 2012: Research details of a drug that may help people with secondary progressive multiple sclerosis (MS), developed by New Zealand biopharmaceutical company Innate Immunotherapeutics, is being highlighted at the worlds biggest annual gathering of MS specialists and pharmaceutical companies, ECTRIMS, in Lyon, France today.
Innates study co-principal investigator, Dr Alison Luckey, will talk about the result of 1B/2A trials of its drug MIS416 in the late breaking news section of ECTRIMS. More than 6,000 people attend the conference.
——-
To view the full article, please click here.
Company Updates
Dogs First to Reduce Risk: QBiotics’ Smarter Path to Oncology Markets
QBiotics took a compound derived from a north Queensland rainforest tree all the way to veterinary registration before pursuing human oncology to de-risk its human cancer programme. Interim CEO Ebru Davidson argues that sequence – now backed by early responses across several human cancers – is the company’s real asset. The story that pulled Wholesale […]
Built on discipline, not complexity: inside an ASX equities income strategy
Haydn Froggatt and Zac Brabin have decades of derivatives experience between them and access to almost any strategy in the market. They use two of the simplest structures available, and wrote 202 positions with them last year. Published by Fairway Capital Management. Based on an interview with co-founders Haydn Froggatt and Zac Brabin. Two traders, […]
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Backed By Leading Investment Groups and Family Offices
